Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» NewLink Genetics writes off pancreatic cancer immunotherapy after phase 3 failure
NewLink Genetics writes off pancreatic cancer immunotherapy after phase 3 failure
NewLink Genetics writes off pancreatic cancer immunotherapy after phase 3 failure
Submitted by
admin
on May 10, 2016 - 10:33am
Source:
BioPharma Dive
News Tags:
NewLink Genetics
pancreatic cancer
algenpantucel-L
Headline:
NewLink Genetics writes off pancreatic cancer immunotherapy after phase 3 failure
Do Not Allow Advertisers to Use My Personal information
